CV week 4 Flashcards
(165 cards)
Secondary Prevention of CAD
actions taken after the development of disease to halt its progress and subsequent complications
-For pts with confirmed CAD or vascular equivalent (AAA, claudication, stroke)
Goal: prevent plaque rupture and progression
Pharmacologic reduction of CV risk with _____, ______ and ______
Anti-platelet
B-Blockers
RAAS Inhibitors
Anti-platelet guidelines for CV risk reduction:
ASA alone? (2)
ASA + Clopidogrel? (1)
ASA or Clopidogrel alone? (2)
ASA alone:
- ALL CAD pts
- low dose for all pts on warfarin
Clopidogrel + ASA:
-all pts with ACS, PCI, or CABG for one year following event
ASA or Clopidogrel alone:
- all symptomatic (not asymptomatic) peripheral artery disease pts
- post-stroke pts (can do both ASA/Clopidogrel together also)
Class I and Class IIa
Beta-blocker guidelines for reducing CAD risk
Class I: B-blocker in all LVSD (EF less than 40%) and HF symptoms or MI/ACS in prior 3 years
Class IIa:
- B-Blockers in all with LVSD (EF less than 40%) even in absence of HF symptoms
- B-blocker in all with any history of MI/ACS
Goal of anti-platelet therapy in CAD secondary prevention:
prevent platelet adhesion to site of ruptured plaque, reduce platelet activation with use of _______, and prevent platelet aggregation with use of _______
ASA
Clopidogrel
Goal of B-blocker therapy in CAD secondary prevention
reduce HR, reduce contractility, reduce conduction velocity, reduce systemic BP → reduce myocardial oxygen demand
Goal of RAAS inhibition in CAD secondary prevention (4)
vasodilation, natriuresis, decreased SNS activity, reduce cardiac remodeling
Class I RAAS inhibition guidelines:
ACEI
ARBs
Aldosterone inhibtion
ACEIs:
-all with LVSD (EF less than 40%), DM, HTN, or chronic kidney disease
ARBs:
-all with LVSD (EF less than 40%) and prior MI or HF symptoms who are ACE INTOLERANT
Aldosterone Inhibition:
- Post MI pts with LVSD (EF less than 40%) who are also taking BB, ACEI/ARB and have HF or DM
- AVOID in renal dysfunction or significant hyperkalemia
BP target goals
> 60yrs –> 150/90
less than 60yrs –> 140/90
Typical strategies for controlling BP
1) Lifestyle (reduce saturated fat/sodium - DASH diet)
2) RAAS inhibitors (ACEis, ARBs)
3) Diuretics
4) Ca2+ channel blockers
5) B-blockers (not the best for HTN)
6) Direct vasodilators (only in certain pts)
Lipid management for CAD secondary prevention
STATINS IN ALL CAD PATIENTS
-High dose statins more efficacious in reducing cardiac events
(Biggest side effect is myalgias)
-Non-statin lipid treatments have been shown to reduce lipid levels, but did NOT reduce cardiac events
Pharmacologic/Lifestyle strategies to reduce CAD risk (5)
1) BP control
2) Lipid management
3) Diabetes management
4) Depression screening and treatment
5) Smoking cessation
Lifestyle strategies for reducing CAD risk
1) Weight management
2) Physical Activity
Role of Monocytes in atherogenesis and disease progression (5)
innate immune system leukocyte
1) Monocytes adhere to endothelial cells expressing VCAM-1 and other adhesion molecules
2) Respond to chemokines (MCP-1) and migrate into intima
3) → Macrophage activation and ingestion of oxLDL → Foam cell
4) Secretion of IL-1, TNF, IFN-y and other proinflammatory mediators
5) Macrophage apoptosis promotes atherosclerosis progression
Role of T cells in atherogenesis and disease progression
Dendritic cell antigen presentation (connection between innate and adaptive immunity)→ T cell activation → clonal T cell expansion (Th1, Th17, Treg)
Th1 and atherogenesis
IFN-y secretion
- Mediates progression of atherosclerosis in conjunction with macrophage apoptosis
- Increases lesion formation and plaque vulnerability
Th17 and atherogenesis
promote plaque instability and angiogenesis (IL-17, IL-22, IL-21 secretion)
Treg and atherogenesis
→ IL-10, TGF-B
Decreased lesion formation and plaque vulnerability
Inflammatory cells and atherogenesis summary
- Immune response to injury initiates atherogenesis
- Innate immune cell interaction with endothelium drives initial plaque formation
- T cells promote further lesion expansion and plaque vulnerability
Drivers of Plaque Instability: (3)
Macrophage apoptosis and necrosis promotes necrotic core
MMPs degrade fibrous cap (Type I collagen)
Intra-plaque hemorrhage further weakens core
CRP
predicts excess risk of CV events (not yet used clinically)
- Acute phase reactant produced by hepatocytes, macrophages, and smooth muscle cells
- Binds to: modified membranes, apoptotic cells, lipoproteins
- Activates classical complement pathway
Link between autoimmune disease and CV events
Treatment of autoimmune disease (psoriasis, RA) associated with a lower risk of CV events
Shows that targeting inflammation can help reduce CV evnts
-TNF-alpha, IL-6, IL-1 inhibition = possible treatment
Risk factors for peripheral artery disease (4)
Diabetes (4x risk)
Smoking (2-3x risk)
Lipids (2x risk)
HTN (2x risk)
Peripheral artery disease results in 6x increased risk of ______
CV death